Document Type
Article
Publication Date
2020
DOI
10.12659/AJCR.928422
Publication Title
The American Journal of Case Reports
Volume
21
Pages
e928422 (1-7)
Abstract
BACKGROUND Icosapent ethyl, a form of eicosapentaenoic acid with anti-inflammatory activity, has been approved as an adjunctive treatment with statins in patients with hypertriglyceridemia. Icosapent ethyl is currently undergoing clinical trials to determine its anti-inflammatory effects in patients with coronavirus disease 2019 (COVID-19). This report describes 3 intensive care unit (ICU) patients with moderate to severe COVID-19 pneumonia treated with icosapent ethyl as part of their supportive care who had favorable outcomes.
CASE REPORT Case 1 was a 75-year-old man with a past medical history of hyperlipidemia, hypertension, type 2 diabetes mellitus, obesity, and benign prostatic hyperplasia. Case 2 was a 23-year old man with a past medical history of type 2 diabetes mellitus and obesity. Case 3 was a 24-year old man with a history of autism. All cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were confirmed from a nasopharyngeal swab using the Becton Dickinson nasopharyngeal reverse-transcription polymerase chain reaction. All patients in these cases were treated with a course of 2 g of icosapent ethyl twice a day by nasogastric tube.
CONCLUSIONS This report of 3 cases describes the use of icosapent ethyl as a component of supportive treatments in ICU patients with moderate to severe COVID-19 pneumonia. However, as of yet there are no evidence-based treatments for SARS-CoV-2 infection from controlled clinical trials. The outcomes of ongoing clinical trials are awaited to determine whether icosapent ethyl has anti-inflammatory effects in patients with SARS-CoV-2 infection and which patients might benefit from the use of this adjunctive treatment.
Original Publication Citation
Suh, W., Urits, I., Viswanath, O., Kaye, A. D., Patel, H., Hall, W., & Eskander, J. P. (2020). Three cases of COVID-19 pneumonia that responded to Icosapent ethyl supportive treatment. The American journal of case reports, 21, 1-7, Article e928422. https://doi.org/10.12659/AJCR.928422
Repository Citation
Suh, Winston; Urits, Ivan; Viswanath, Omar; Kaye, Alan D.; Patel, Haresh; Hall, Wade; and Eskander, Jonathan P., "Three Cases of COVID-19 Pneumonia That Responded to Icosapent Ethyl Supportive Treatment" (2020). Nursing Faculty Publications. 49.
https://digitalcommons.odu.edu/nursing_fac_pubs/49
Comments
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.